【摘要】 目的探讨胰腺癌根治术后行吉西他滨联合替吉奥胶囊化疗的临床疗效。方法将60例胰腺癌根治术后患者随机分为给予吉西他滨联合替吉奥胶囊化疗的观察组和吉西他滨联合紫杉醇化疗的对照组,观察2组患者的生活质量、疗效、不良反应及肿瘤内分泌指标。结果观察组生活质量化疗后2周(81.1±9.5)、4周(84.8±10.4)、8周(90.3±12.9)、12周(95.2±13.8),sFlt-1水平(178.3±23.1),平均生存时间[(32.7±6.5)月]、2年生存率(66.7%)、3年生存率(40.0%)均明显高于对照组;心、肝、肾功能损害发生率(20.0%)、VEGF水平(63.2±9.5)均低于对照组(P<0.05)。结论吉西他滨联合替吉奥胶囊化疗能够改善胰腺癌根治术后患者的生活质量,具有积极的临床价值。更多还原

【Abstract】 Objective To study clinical efficacy of gemcitabine combined with S-1 capsule for pancreatic cancer patients treated with radical resection. Methods 60 cases of pancreatic cancer patients who received radical resection were randomly divided into the observation group( given gemcitabine combined with S-1 capsule) and the control group( given gemcitabine and paclitaxel). Quality of life,efficacy,adverse reactions and tumor endocrine index of the 2 groups were observed. Results In the observation group,quality of life of were( 81. 1 ± 9. 5),( 84. 8 ± 10. 4),( 90. 3 ± 12. 9) and( 95. 2 ± 13. 8) 2,4,8 and 12 weeks after chemotherapy,respectively; and sFlt-1 level was( 178. 3 ± 23. 1),average survival time was( 32. 7 ± 6. 5) months; 2-and 3-year survival rates were 66. 7% and 40. 0%. The above items of the observation group were significantly higher than those of the control group. Incidence of heart,liver and kidney function damage( 20. 0%) and VEGF level( 63. 2 ± 9. 5) were lower than those of the control group. Conclusion Gemcitabine combined with S-1 capsule can improve life quality of pancreatic cancer patients treated with radical resection,and it has positive clinical value.更多还原